IL-23 Antibody (D-12): sc-271349

IL-23 Antibody (D-12) is a mouse monoclonal IgG2b antibody that detects IL-23 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IL-23 is a crucial cytokine that plays a significant role in the immune response, particularly in the differentiation and maintenance of T helper 17 (Th17) cells, which are essential for combating certain pathogens and mediating autoimmune diseases. IL-23 promotes the production of pro-inflammatory cytokines, thereby influencing the development of various inflammatory conditions. IL-23 is composed of two subunits: p19 and p40, with p19 being the unique component that distinguishes IL-23 from IL-12. IL-23′s interaction with its receptor activates signaling pathways that lead to the production of additional inflammatory mediators, highlighting IL-23′s role in both protective immunity and pathological inflammation. The gene encoding IL-23 is located on human chromosome 12, and IL-23′s dysregulation has been implicated in several autoimmune disorders, making IL-23 a target for therapeutic intervention. Anti-IL-23 antibody (D-12) is an invaluable tool for researchers studying the complex roles of this cytokine in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IL-23 Antibody (D-12) References:

1. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.  |  Gravallese, EM. and Schett, G. 2018. Nat Rev Rheumatol. 14: 631-640. PMID: 30266977
2. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs.  |  Hewitt, SL., et al. 2019. Sci Transl Med. 11: PMID: 30700577
3. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.  |  Li, H. and Tsokos, GC. 2021. Clin Rev Allergy Immunol. 60: 31-45. PMID: 33185790
4. IL-23 orchestrating immune cell activation in arthritis.  |  Najm, A. and McInnes, IB. 2021. Rheumatology (Oxford). 60: iv4-iv15. PMID: 34668017
5. The emerging role of IL-23 in asthma and its clinical implications.  |  Wu, AY. and Peebles, RS. 2023. Expert Rev Clin Immunol. 19: 1-5. PMID: 36106675
6. The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease.  |  Korta, A., et al. 2023. Int J Mol Sci. 24: PMID: 37373318
7. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.  |  Steere, B., et al. 2023. J Pharmacol Exp Ther. 387: 180-187. PMID: 37714687
8. Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade.  |  Francis, L., et al. 2024. Nat Commun. 15: 913. PMID: 38291032
9. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.  |  Fourie, AM., et al. 2024. Sci Rep. 14: 17515. PMID: 39080319
10. IL-23 inhibition for chronic inflammatory disease.  |  Jairath, V., et al. 2024. Lancet. 404: 1679-1692. PMID: 39461795

The preferred IL-23 antibody is IL-23 Antibody (C-3): sc-271279.